Zacks Investment Research
11 Nov 2025, 00:56 UTC · 50w ago
Verdict
Headline takes no side. We score OBIO −0.30 across three claims — moderately bearish.
−0.30moderately bearish
More negative than 75% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Orchestra BioMed Holdings reported a quarterly loss of $0.40 per share, missing the Zacks Consensus Estimate of a $0.38 loss.
So whatAn earnings miss of -5.26% directly signals weaker-than-expected profitability, which typically pressures the stock price lower.
More negative than 95% of claims this week
Orchestra BioMed has surpassed consensus EPS estimates just once over the last four quarters.
So whatA poor track record of meeting earnings expectations reduces investor confidence in the company's forward guidance and reliability.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 87% of claims this week
The company reported quarterly revenues of $0.86 million, beating the consensus estimate by 15.42% but declining from $0.99 million a year ago.
More positive than 62% of claims this week
Which stocks this story touches
More negative than 75% of ticker scores this week
The company reported an earnings miss with a quarterly loss of $0.40 per share versus estimates and has underperformed the S&P 500 this year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
+51.2%
Price is moving against the score
$5.71 vs $3.78 close before publication (Nov 10) · not market-adjusted
OBIO chart →
